The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Top Cited Papers
- 1 January 2015
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 16 (1), 25-35
- https://doi.org/10.1016/s1470-2045(14)71159-3
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerThe New England Journal of Medicine, 2012
- Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer TherapyJNCI Journal of the National Cancer Institute, 2012
- ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast CancerCancer Discovery, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast CancerJournal of Clinical Oncology, 2009
- PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroBreast Cancer Research, 2009
- Cell cycle, CDKs and cancer: a changing paradigmNature Reviews Cancer, 2009
- Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer GroupJournal of Clinical Oncology, 2003
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994